Business
RepliCel Life Sciences Inc. Announces Closing of Second Tranche of Private Placement
RepliCel Life Sciences Inc. Announces Closing of Second Tranche of Private Placement.
About this update from Replicel Life Sciences Inc.
[{"type":"text","content":"\n\n\n\n\nMarketwire\n\n\n\n\nRepliCel Life Sciences Inc. Announces Closing of Second Tranche of Private Placement\n\n\n\n\n\n\n\n\n\n VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 24, 2015) - \n NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES\n RepliCel Life Sciences Inc. (\"RepliCel\" or the \"Company\") (OTCQB:REPCF)(TSX VENTURE:RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to announce it has closed the second tranche of its financing announced on October 20, 2015, which consisted of a brokered private placement of 119,000 units (each a \"Unit\") at a price of $0.31 per Unit for gross proceeds of $36,890 (the \"Brokered Financing\") and a non-brokered private placement of 100,000 Units at a price of $0.31 per Unit for gross proceeds of $31,000.00. Each Unit consists of one common share of the Company (each, a \"Share\") and one Share purchase warrant, which entitles the holder to purchase one additional Share for a period of two years from the closing of the private placement at a price of $0.40 per Share.\n Euro Pacific Canada Inc. and Richardson GMP Limited (collectively, the \"Agents\") acted as the agents with respect to the Brokered Financing. The Agents and members of the selling group also received options to purchase an aggregate of 9,520 Units of the Company at a price of $0.31 per Unit for a period of 24 months and received cash commission of $2,951.20 \n All securities issued pursuant to the financing will be subject to a statutory hold period expiring four months and one day after closing of the financing. None of the securities issued in the financing have been registered under the United States Securities Act of 1933, as amended (the \"1933 Act\"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.\n Proceeds of the financing are anticipated to be used for clinical trials, research and development and general working capital.\n About RepliCel Life Scien...